Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
NCT ID: NCT00688610
Last Updated: 2009-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
571 participants
INTERVENTIONAL
2007-11-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observation of Initial Procalcitonin and the Clinical Course of Patients With Acute Respiratory Tract Infections
NCT00827060
Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study
NCT00099840
POCT PCT in Outpatient LRTI
NCT05380869
Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections
NCT02171338
Improving Antibiotic Use in Acute Care Treatment
NCT00144040
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laboratory value procalcitonin
A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is not recommended, patient shall not take antibiotic. In case of "retention of decision": patient may take the antibiotic.
B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either "change of decision" or "retention of decision". In case of "change decision": antibiotic is recommended, patient has to be informed about. In case of "retention of decision": no change.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
* Respiratory tract infection based on the clinical judgement of the primary care physician
Exclusion Criteria
* Portal hypertension
* Major surgeries or multiple trauma which require hospitalization, in previous 4 weeks
* Autoimmune disease and systemic diseases (lupus erythematodes, wegener´s disease)
* Peritoneal dialysis
* Acute treated or recently operated medullary c-cell-carcinoma, SCLC, carcinoid
* Other inflammatory diseases (e.g. urinary tract infection, pyelonephritis, pancreatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hannover Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. med. Tobias Welte
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olaf Burkhardt, Dr.
Role: PRINCIPAL_INVESTIGATOR
Medical School Hannover
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical School Hannover, Department Pneumology
Hanover, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, Hummers-Pradier E, Welte T. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010 Sep;36(3):601-7. doi: 10.1183/09031936.00163309. Epub 2010 Feb 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HannoverPro II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.